TRACON Pharmaceuticals, Inc. Common Stock
TCON
TCON was delisted on the 27th of June, 2024.
31 hedge funds and large institutions have $19.7M invested in TRACON Pharmaceuticals, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 6 closing their positions.
166% more call options, than puts
Call options by funds: $125K | Put options by funds: $47K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
11% less funds holding
Funds holding: 35 → 31 (-4)
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
18% less capital invested
Capital invested by funds: $24M → $19.7M (-$4.27M)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$1.88M |
| 2 |
Millennium Management
New York
|
+$146K |
| 3 |
TI
Telemetry Investments
New York
|
+$63.9K |
| 4 |
Renaissance Technologies
New York
|
+$45.3K |
| 5 |
BlackRock
New York
|
+$11.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
-$146K |
| 2 |
Franklin Resources
San Mateo,
California
|
-$115K |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$105K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$96.3K |
| 5 |
Two Sigma Advisers
New York
|
-$93.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
26
Tower Research Capital (TRC)
New York
| $3K | +$2.63K | +68 | +523% |
|
|
CG
27
Cutler Group
San Francisco,
California
| $2K | -$29K | -750 | -93% |
|
28
Wells Fargo
San Francisco,
California
| $2K | +$39 | +1 | +2% |
|
|
TWA
29
TCI Wealth Advisors
Tucson,
Arizona
| $1K | – | – | – |
|
|
TC
30
Truvestments Capital
Sarasota,
Florida
| $1K | +$619 | +16 | New |
|
|
31
Citadel Advisors
Miami,
Florida
| – | -$96.3K | -2,487 | Closed |
|
|
32
Franklin Resources
San Mateo,
California
| – | -$115K | -2,185 | Closed |
|
33
Dimensional Fund Advisors
Austin,
Texas
| – | -$51K | -978 | Closed |
|
34
Simplex Trading
Chicago,
Illinois
| – | -$20.7K | -536 | -98% |
|
35
UBS Group
Zurich,
Switzerland
| – | -$13K | -241 | Closed |
|
36
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$11K | -200 | Closed |
|
37
Morgan Stanley
New York
| – | -$5K | -97 | Closed |
|
TCON Hedge Fund Activity: Q2 2022 in Review
31 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in TRACON Pharmaceuticals, Inc. Common Stock (TCON) for Q2 2022, worth a combined $19.7M — down 18% from $24M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of TCON and 2 opened new positions — a net loss of 4 holders — while 8 trimmed existing stakes and 7 added.
The largest buyer was Opaleye Management, adding an estimated $1.88M. The largest seller was Bank of New York Mellon, cutting an estimated $146K.
- 31 institutional investors held TRACON Pharmaceuticals, Inc. Common Stock (TCON) as of Q2 2022, down from 35 in Q1 2022.
- Funds reported $19.7M of TRACON Pharmaceuticals, Inc. Common Stock stock for Q2 2022, down 18% quarter-over-quarter.
- 2 funds opened new TRACON Pharmaceuticals, Inc. Common Stock positions in Q2 2022 and 6 closed out, a net change of -4 holders.
- The largest TRACON Pharmaceuticals, Inc. Common Stock buyer in Q2 2022 was Opaleye Management, an estimated $1.88M added.
- The largest TRACON Pharmaceuticals, Inc. Common Stock seller in Q2 2022 was Bank of New York Mellon, an estimated $146K sold.
Based on aggregated 13F filings for Q2 2022.